RFI 641

Drug Profile

RFI 641

Latest Information Update: 21 Mar 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Class Antivirals; Triazines
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 21 Mar 2002 Discontinued - Clinical-Phase-Unknown for Respiratory syncytial virus infections in USA (unspecified route)
  • 23 Feb 2001 A preclinical study has been added to the Viral Infections pharmacodynamics section
  • 12 Oct 2000 A preclinical study has been added to the adverse events and Viral infections antimicrobial activity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top